Cover Image
市場調查報告書

膽汁性肝硬化 :開發平台分析

Biliary Cirrhosis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 199644
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
膽汁性肝硬化 :開發平台分析 Biliary Cirrhosis - Pipeline Review, H2 2015
出版日期: 2015年07月29日 內容資訊: 英文 82 Pages
簡介

膽汁性肝硬化是可能長期造成肝臟硬化的慢性肝臟疾病。常見的症狀有疲勞感、皮膚發癢、乾眼症、黃疸、腳和腳踝浮腫等。年齡和感染經歷是致病因素。

本報告提供膽汁性肝硬化的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

膽汁性肝硬化 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • AlbireoPharma
  • Dr. Falk Pharma GmbH
  • GlaxoSmithKline plc
  • Intercept Pharmaceuticals, Inc.
  • Johnson & Johnson
  • MediGene AG
  • NGM Biopharmaceuticals, Inc.
  • Shire Plc
  • Virobay Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • A-4250
  • budesonide
  • FFP-104
  • GSK-2330672
  • Leukothera
  • NGM-282
  • obeticholic acid
  • RhuDex
  • SHP-625
  • ustekinumab
  • VBY-825

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6886IDB

Summary

Global Markets Direct's, 'Biliary Cirrhosis - Pipeline Review, H2 2015', provides an overview of the Biliary Cirrhosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Biliary Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Biliary Cirrhosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Biliary Cirrhosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Biliary Cirrhosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Biliary Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Biliary Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Biliary Cirrhosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Biliary Cirrhosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Biliary Cirrhosis Overview
  • Therapeutics Development
    • Pipeline Products for Biliary Cirrhosis - Overview
    • Pipeline Products for Biliary Cirrhosis - Comparative Analysis
  • Biliary Cirrhosis - Therapeutics under Development by Companies
  • Biliary Cirrhosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Biliary Cirrhosis - Products under Development by Companies
  • Biliary Cirrhosis - Companies Involved in Therapeutics Development
    • AlbireoPharma
    • CymaBay Therapeutics, Inc.
    • Dr. Falk Pharma GmbH
    • Enanta Pharmaceuticals, Inc.
    • GlaxoSmithKline Plc
    • Intercept Pharmaceuticals, Inc.
    • Johnson & Johnson
    • MediGene AG
    • NGM Biopharmaceuticals, Inc.
    • Shire Plc
    • Virobay Inc.
  • Biliary Cirrhosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-4250 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FFP-104 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-2330672 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-8025 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NGM-282 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RhuDex - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-625 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ustekinumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBY-825 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Biliary Cirrhosis - Recent Pipeline Updates
  • Biliary Cirrhosis - Dormant Projects
  • Biliary Cirrhosis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 29, 2015: Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
      • Apr 13, 2015: Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015
      • Mar 24, 2015: NGM Biopharmaceuticals Announces Positive Phase 2 Clinical Data in Primary Biliary Cirrhosis Patients for NGM282, a First-in-Class Investigational Medicine
      • Feb 05, 2015: Initiation of a Phase II Trial for A4250, the Company's Lead Compound for Cholestatic Liver Diseases and NASH
      • Nov 08, 2014: Intercept Announces Additional Data for OCA in Primary Biliary Cirrhosis
      • May 28, 2014: Intercept Announces that FDA Grants Fast Track Designation to Obeticholic Acid for the Treatment of Patients with Primary Biliary Cirrhosis
      • Apr 12, 2014: Intercept Reports Additional Positive Data From POISE Trial at EASL Late-Breaker Session
      • Apr 11, 2014: Intercept Announces Preclinical Data Demonstrating OCA's Potential Role in Preventing Complications of Cirrhosis
      • Apr 04, 2014: Data From Intercept's Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014
      • Mar 16, 2014: Intercept Announces Positive Pivotal Phase 3 POISE Trial Results
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Biliary Cirrhosis, H2 2015
  • Number of Products under Development for Biliary Cirrhosis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Biliary Cirrhosis - Pipeline by AlbireoPharma, H2 2015
  • Biliary Cirrhosis - Pipeline by CymaBay Therapeutics, Inc., H2 2015
  • Biliary Cirrhosis - Pipeline by Dr. Falk Pharma GmbH, H2 2015
  • Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals, Inc., H2 2015
  • Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Biliary Cirrhosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015
  • Biliary Cirrhosis - Pipeline by Johnson & Johnson, H2 2015
  • Biliary Cirrhosis - Pipeline by MediGene AG, H2 2015
  • Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2015
  • Biliary Cirrhosis - Pipeline by Shire Plc, H2 2015
  • Biliary Cirrhosis - Pipeline by Virobay Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Biliary Cirrhosis Therapeutics - Recent Pipeline Updates, H2 2015
  • Biliary Cirrhosis - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Biliary Cirrhosis, H2 2015
  • Number of Products under Development for Biliary Cirrhosis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top